Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Cited by (1,000)

Items 401–500 of 1,000

1. p53 Nuclear Expression Correlates With Hemizygous TP53 Deletion and Predicts an Adverse Outcome for Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide
   Mei-Hsi Chen, Connie X.Y. Qi, Manujendra N. Saha, Hong Chang · 2012 · American Journal of Clinical Pathology
2. Novel agents and new therapeutic approaches for treatment of multiple myeloma
   Roberto Ria · 2014 · World Journal of Methodology
3. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib
   Jörgen Möller, Lars Nicklasson, Ananthram Murthy · 2011 · Journal of Medical Economics
4. Role of new treatment approaches in defining treatment goals in multiple myeloma – the ultimate goal is extended survival
   Brian G.M. Durie · 2010 · Cancer Treatment Reviews
5. Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
   Ivetta Danylesko, Katia Beider, Avichai Shimoni, Arnon Nagler · 2012 · Clinical and Developmental Immunology
6. Current Therapeutic Strategy for Multiple Myeloma
   Kenshi Suzuki · 2013 · Japanese Journal of Clinical Oncology
7. Treating Multiple Myeloma Patients With Oral Therapies
   Shaji Kunnathu Kumar, Ravi Vij, Stephen Joseph Noga, Deborah T. Berg, Lonnie D. Brent, Lawrence E Dollar, Ajai Chari · 2017 · Clinical Lymphoma Myeloma & Leukemia
8. The cost‐effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective
   John C Hornberger, JB Rickert, Ravinder Dhawan, Johan Liwing, JOHAN ASCHAN, Mikael Löthgren · 2010 · European Journal Of Haematology
9. Prognostic Effect of Comorbidity Indices in Elderly Patients With Multiple Myeloma
   Jelena Bila, Jelena Jelicic, Vladislava Djurasinovic, Vojin Vuković, Aleksandra Sretenović, Bosko Andjelic, Darko A. Antic, Milena Todorović, Biljana Mihaljević · 2015 · Clinical Lymphoma Myeloma & Leukemia
10. Lenalidomide — The Phoenix Rises
    Alan F. List · 2007 · New England Journal of Medicine
11. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Geetika Srivastava, Vishal Rana, Martha Q. Lacy, Francis K. Buadi, Suzanne R. Hayman, Angela A. Dispenzieri, Morie Abraham Gertz, David Dingli, Steven R. Zeldenrust, Stephen J. Russell et al. · 2013 · Leukemia
12. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma
    Sagar Lonial, Jonathan L. Kaufman, Jacob P. Laubach, Paul Gerard Guy Richardson · 2013 · Expert Opinion on Biological Therapy
13. The evolution and impact of therapy in multiple myeloma
    Jacob P. Laubach, Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2010 · Medical Oncology
14. Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives
    Andrzej J. Jakubowiak · 2012 · Seminars in Hematology
15. Absence of Exposed Bone Following Dental Extraction in Beagle Dogs Treated With 9 Months of High-Dose Zoledronic Acid Combined With Dexamethasone
    Matthew R. Allen, Tien‐Min Gabriel Chu, Salvatore L. Ruggiero · 2013 · Journal of Oral and Maxillofacial Surgery
16. Relapsed and refractory multiple myeloma: A systematic review and network meta‐analysis of the efficacy of novel therapies
    Daisuke Minakata, Shin‐ichiro Fujiwara, Daizo Yokoyama, Atsuto Noguchi, Shuka Aoe, Takashi Oyama, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo et al. · 2023 · British Journal of Haematology
17. Management of myeloma-associated renal dysfunction in the era of novel therapies
    Mahmoud Gaballa, Jacob P. Laubach, Robert L Schlossman, Katherine Redman, Kimberly Noonan, Constantine S. Mitsiades, Irene M. Ghobrial, Nikhil C. Munshi, Kenneth Carl Anderson, Paul Gerard Guy Richardson · 2012 · Expert Review of Hematology
18. Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010
    Jean‐Luc Harousseau · 2010 · Clinical Lymphoma Myeloma & Leukemia
19. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study
    Xavier Armoiry, Francis Fagnani, Lotfi Benboubker, Thierry T.F. Facon, Jean‐Paul Fermand, Cyrille Hulin, Philippe Moreau, G. Aulagner · 2010 · Journal of Clinical Pharmacy and Therapeutics
20. Stability of lenalidomide suspension after preparation by a simple suspension method for enteral tube administration
    Tomoko O Morita, Ayumi Yamaguchi, Sadaaki Kimura, Hirofumi Fujii, Kazushi Endo, Keishiro Izumi, Shinichiro Saito, Hironobu Minami · 2015 · Journal of Oncology Pharmacy Practice
21. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen
    Aziz Nazha, R Cook, Dan T. Vogl, Patricia A Mangan, Marie Gardler, Kimberly Hummel, K. Cunningham, Selina M. Luger, David Porter, Stephen J. Schuster et al. · 2010 · Bone Marrow Transplantation
22. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma
    Sagar Lonial, Jamie D. Cavenagh · 2009 · British Journal of Haematology
23. Pomalidomide therapy for myeloma
    Stephen Schey, Karthik Ramasamy · 2011 · Expert Opinion on Investigational Drugs
24. Renal Complications in Multiple Myeloma and Related Disorders
    Beth M Faiman, Patricia A Mangan, Jacy Spong, Joseph D Tariman · 2011 · Clinical journal of oncology nursing
25. Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
    Federica Costa, Rosanna Vescovini, Marina Bolzoni, Valentina Marchica, Paola Storti, Denise Toscani, Fabrizio Accardi, Laura Notarfranchi, Benedetta Dalla Palma, Cristina Manferdini et al. · 2017 · Oncotarget
26. Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013
    Martin Andres, Anita Feller, Volker Arndt · 2018 · Cancer Epidemiology
27. The Development and Pharmacology of Proteasome Inhibitors for the Management and Treatment of Cancer
    Bruce Ruggeri, Sheila J. Miknyoczki, Bruce D. Dorsey, Ai‐Min Hui · 2009 · Advances in pharmacology
28. Inherited thrombotic thrombocytopenic purpura
    Miriam Galbusera, Marina Noris, Giuseppe Remuzzi · 2009 · Haematologica
29. Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
    Urmeel Patel, Muhammad Ayaz Mir, Jeffrey Michael Sivik, Divisha Raheja, Manoj Kumar Pandey, Giampaolo Talamo · 2015 · Hematology Reports
30. The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases
    Fabio Cofano, Matteo Monticelli, Marco Ajello, Francesco Zenga, Nicola Marengo, Giuseppe Di Perna, Roberto Altieri, Paola Cassoni, Luca Bertero, Antonio Melcarne et al. · 2019 · Cancer Control
31. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077
    Wolfram Pönisch, Simone Heyn, Juliane Beck, Ina Wagner, Martin Mohren, Franz Albert Hoffmann, Thoralf Lange, Marion Schmalfeld, Thomas Zehrfeld, Andreas Schwarzer et al. · 2013 · British Journal of Haematology
32. Future agents and treatment directions in multiple myeloma
    Enrique M. Ocio, Constantine S. Mitsiades, Robert Zygmunt Orlowski, Kenneth Carl Anderson · 2013 · Expert Review of Hematology
33. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
    Gordon Cook, Sonja Zweegman, María‐Victoria Mateos, Florence Suzan, Philippe Moreau · 2017 · Critical Reviews in Oncology/Hematology
34. The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe
    Michèle Cavo, Evangelos Terpos, Joan Bargay, Hermann Einsele, Jim Cavet, Richard Greil, Edwin de Wit · 2018 · Expert Review of Hematology
35. Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction
    Muhammad Asad Fraz, Faiza Hassan Warraich, Sami Ullah Warraich, Muhammad Junaid Tariq, Zabih Warraich, Ali Younas Khan, Muhammad Usman, Awais Ijaz, Pavan Tenneti, Adeela Mushtaq et al. · 2019 · Critical Reviews in Oncology/Hematology
36. Lenalidomide enhances the anti‐prostate cancer activity of docetaxel in vitro and in vivo
    Jake Y. Henry, Ling Lu, Mary Adams, Brendan Meyer, J. Blake Bartlett, Angus George Dalgleish, Christine Galustian · 2011 · The Prostate
37. Toxic neuropathy
    Hadi Manji · 2011 · Current Opinion in Neurology
38. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma
    Antonio Pierangelo Palumbo, Pieter Sonneveld · 2015 · Expert Review of Hematology
39. Expanding role of lenalidomide in hematologic malignancies
    Nilanjan Ghosh, Michael Richard Grunwald, Omotayo O. Fasan, Manisha Bhutani · 2015 · Cancer Management and Research
40. No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
    Nianhang Chen, Daniel Weiss, Josephine F. Reyes, Liangang Liu, Claudia Kasserra, Xiaomin Wang, Simon Yuji Zhou, Gondi N. Kumar, Lilia Weiss, Maria Palmisano · 2014 · Cancer Chemotherapy and Pharmacology
41. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
    Dan T. Vogl, Edward Allen Stadtmauer, Paul Gerard Guy Richardson, Pieter Sonneveld, Michael W. Schuster, David H. Irwin, Thierry T.F. Facon, Jean‐Luc Harousseau, Anthony L. Boral, Rachel Neuwirth et al. · 2009 · British Journal of Haematology
42. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma
    Giovanni Barosi, Giampaolo Merlini, Atto Billio, Mario Boccadoro, Paolo Corradini, Monia Marchetti, Massimo Massaia, Patrizia Tosi, Antonio Palumbo, Michèle Cavo et al. · 2012 · Annals of Hematology
43. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond
    Andrew A. Guirguis, Benjamin L. Ebert · 2015 · Current Opinion in Cell Biology
44. How I treat relapsed myeloma
    Joan Bladé, Laura Rosiñol, Carlos Fernández de Larrea · 2015 · Blood
45. Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis
    Nidhi Tandon, Surbhi Sidana, Morie Abraham Gertz, Angela A. Dispenzieri, Martha Q. Lacy, Francis K. Buadi, David Dingli, Amie L Fonder, Miriam Hobbs, Suzanne R. Hayman et al. · 2017 · American Journal of Hematology
46. Immunomodulatory drugs in the treatment of multiple myeloma
    Yu Abe, Tadao Ishida · 2019 · Japanese Journal of Clinical Oncology
47. Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma
    Shigeyuki Yokokura, Saki Yurimoto, Akihito Matsuoka, Osamu Imataki, Hiroaki Dobashi, Shuji Bandoh, Takuya Matsunaga · 2014 · BMC Cancer
48. Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients
    Rouslan Kotchetkov, Esther Masih‐Khan, Chia‐Min Chu, Eshetu G. Atenafu, Christine I. Chen, Vishal Kukreti, Suzanne Trudel, Rodger Edwin Tiedemann, Donna Ellen Reece · 2016 · Cancer Medicine
49. History of Multiple Myeloma
    Robert A. Kyle, David P. Steensma · 2011 · Recent results in cancer research/Recent Results in Cancer Research
50. Lenalidomide in multiple myeloma: Current status and future potential
    Hang Quach, Anna Kalff, Andrew G Spencer · 2012 · American Journal of Hematology
51. Current approaches for the treatment of multiple myeloma
    Reiko Watanabe, Michihide Tokuhira, Masahiro Kizaki · 2013 · International Journal of Hematology
52. Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment
    Norbert Grząśko, Marta Morawska, Marek Hus · 2014 · Clinical Lymphoma Myeloma & Leukemia
53. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?
    Patrícia Melo Aguiar, Tácio de Mendonça Lima, Sı́lvia Storpirtis · 2016 · Journal of Clinical Pharmacy and Therapeutics
54. IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation
    Shirong Li, Jing Fu, Hui Wang, Huihui Ma, Xiaoming Xu, Yong‐Guang Yang, Shi‐Xian Deng, Markus Y. Mapara, Suzanne Lentzsch · 2018 · Blood Advances
55. Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
    Sarah A. Holstein, Vera Jean Suman, Philip L. McCarthy · 2019 · Current Hematologic Malignancy Reports
56. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
    Danai Dima, Fauzia Ullah, Sandra Ann Mazzoni, Louis S. Williams, Beth M Faiman, Austin Kurkowski, Chakra P. Chaulagain, Shahzad Raza, Christy Joy Samaras, Jason Neil Valent et al. · 2023 · Cancers
57. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
    Sung‐Hoon Jung, Hyunju Lee, Youn-Kyung Lee, Deok‐Hwan Yang, Hyeoung‐Joon Kim, Joon Haeng Rhee, Frank Emmrich, Je‐Jung Lee · 2017 · Oncotarget
58. Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity
    Yuki Fujiwara, Yi Sun, Robert J. Torphy, Jiadai He, Katsuhiko K. Yanaga, Barish H. Edil, Richard David Schulick, Yuwen Zhu · 2018 · Cancer Research
59. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
    Geoffrey L. Uy, Sagun D. Goyal, Nicholas M. Fisher, A Y Oza, Michael H. Tomasson, Keith E Stockerl-Goldstein, John F. DiPersio, Ravi Vij · 2008 · Bone Marrow Transplantation
60. Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma
    María‐Victoria Mateos, Enrique M. Ocio, Jesús F. San Miguel · 2013 · Seminars in Oncology
61. Novel Therapeutic Targets for Multiple Myeloma
    Anuj Kumar Mahindra, Diana D. Cirstea, Noopur S Raje · 2010 · Future Oncology
62. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis
    Meletios Athanasios Dimopoulos, Jonathan L. Kaufman, Darrell J. White, Gordon Cook, Maria Rizzo, Yingxin Xu, Kyle R. Fahrbach, Maren Gaudig, Mary Slavcev, Lindsay Dearden et al. · 2018 · Clinical Lymphoma Myeloma & Leukemia
63. How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
    de Arriba de la Fuente, Felipe, Montes Gaisán, Carmen, de la Rubia Comos, Javier · 2022 · Cancers
64. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience
    Adrián Macías Alegre, Albert Oriol, José García‐Laraña, María‐Victoria Mateos, Anna Maria Sureda, Carmen Martínez‐Chamorro, María Teresa Cibeira, Beatriz Aguado, Robert Knight, Barbara Rosettani · 2012 · Leukemia & lymphoma/Leukemia and lymphoma
65. Lenalidomide in combination with R‐ ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: a phase 1b study from GELTAMO group
    Alejandro Martı́n, Alba Redondo, Iván Dlouhy, Antonio Salar, Eva M. González-Barca, Miguel Ángel Canales, Santiago Montes‐Moreno, Enrique M. Ocio, Armando López‐Guillermo, Dolores M. Caballero et al. · 2016 · British Journal of Haematology
66. Recent advances in multiple myeloma: a Korean perspective
    Junshik Hong, Jae Hoon Lee · 2016 · The Korean Journal of Internal Medicine
67. Triplet vs. doublet drug regimens for managing multiple myeloma
    Massimo Offidani, Laura Corvatta, Silvia Gentili · 2017 · Expert Opinion on Pharmacotherapy
68. Multiple myeloma: management of adverse events
    Francesca Gay, Antonio Palumbo · 2009 · Medical Oncology
69. Profile of elotuzumab and its potential in the treatment of multiple myeloma
    Frits van Rhee, Yi‐Chang Liu, Susann M. Szmania · 2014 · Blood and Lymphatic Cancer Targets and Therapy
70. In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465
    Joseph M. Negri, Douglas W. McMillin, Jake E. Delmore, Nicholas Mitsiades, Patrick John Hayden, Steffen Klippel, Teru Hideshima, Dharminder Chauhan, Nikhil C. Munshi, Carolyn A. Buser et al. · 2009 · British Journal of Haematology
71. How lenalidomide is changing the treatment of patients with multiple myeloma
    Meletios Athanasios Dimopoulos, Evangelos Terpos, Rubén Niesvizky · 2013 · Critical Reviews in Oncology/Hematology
72. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
    Hang Quach, Liam Joseph Fernyhough, Ross Alistair Henderson, Gillian Corbett, Bart Baker, Peter Browett, Hilary Anne Blacklock, Cecily J. Forsyth, Craig R. Underhill, Paul Cannell et al. · 2017 · British Journal of Haematology
73. A functional three-dimensional microphysiological human model of myeloma bone disease
    Richard J. Visconti, Kyle L. Kolaja, Jessica Ann Cottrell · 2020 · Journal of Bone and Mineral Research
74. Prognostic Risk Factor Evaluation in Patients With Relapsed or Refractory Multiple Myeloma Receiving Lenalidomide Treatment: Analysis of Renal Function by eGFR and of Additional Comorbidities by Comorbidity Appraisal
    Martina Kleber, Gabriele Ihorst, Josefina Udi, Bernd Koch, Ralph Wäsch, Monika Martha Engelhardt · 2011 · Clinical Lymphoma Myeloma & Leukemia
75. Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues
    Thoralf Christoffersen, Tormod Kyrre Guren, Karen‐Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen · 2009 · European Journal of Pharmacology
76. Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma
    Maria Caterina Pallotti · 2014 · World Journal of Gastroenterology
77. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide
    Vittorio Montefusco, Monica Galli, Francesco Spina, Paola Stefanoni, Alberto Mussetti, Giulia Perrone, Chiara De Philippis, Serena Camilla Dalto, Francesco Maura, Chiara Bonini et al. · 2014 · Leukemia & lymphoma/Leukemia and lymphoma
78. Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
    Xavier P Leleu, Francesca Gay, Anne Flament, Kim Allcott, Michel Delforge · 2017 · Annals of Hematology
79. Management of Relapsed and Relapsed/Refractory Multiple Myeloma
    Jacob P. Laubach, Constantine S. Mitsiades, Anuj Kumar Mahindra, Marlise Rachael Luskin, Jacalyn M. Rosenblatt, Irene M. Ghobrial, Robert L Schlossman, David Avigan, Noopur S Raje, Nikhil C. Munshi et al. · 2011 · Journal of the National Comprehensive Cancer Network
80. Total cost comparison in relapsed/refractory multiple myeloma
    Brian G.M. Durie, G. Binder, Chris Leo Pashos, Zeba M. Khan, Mohamad A. Hussein, Ivan Borrello · 2013 · Journal of Medical Economics
81. Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT
    H-Y Yhim, Kihyun Kım, Jin Seok Kim, Hye Jin Kang, J-A Kim, C-K Min, Sung Hwa Bae, E. Park, D-H Yang, Cheolwon Suh et al. · 2012 · Bone Marrow Transplantation
82. Successful Treatment of Patients With Multiple Myeloma and Impaired Renal Function With Lenalidomide: Results of 4 German Centers
    Katharina Oehrlein, Christian Langer, Isrid Sturm, Wolfram Pönisch, Corinna Hahn‐Ast, Sigrid Kuhn, Katja Christina Weisel · 2012 · Clinical Lymphoma Myeloma & Leukemia
83. Treating venous thromboembolism in patients with cancer
    Caroline Irene Piatek, Casey Lee O'Connell, Howard A. Liebman · 2012 · Expert Review of Hematology
84. Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective
    Madhav Desai, Kate Juliet Newberry, Zhishuo Ou, Michael L. Wang, Liang Zhang · 2014 · Therapeutic Advances in Hematology
85. Novel therapies for relapsed myeloma
    A. Keith Stewart · 2009 · Hematology
86. Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy (Review)
    Ting Liu, Feng Guo, Xiaomin Zhu, Xiangge He, Lin Xie · 2017 · Experimental and Therapeutic Medicine
87. Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention
    Dae Hyun Lee, Michael G. Fradley · 2018 · Current Treatment Options in Cardiovascular Medicine
88. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study
    Ajai Chari, Niels W.C.J. van de Donk, Bhagirathbhai Dholaria, Katja Christina Weisel, María‐Victoria Mateos, Hartmut Goldschmidt, Thomas G. Martin, Daniel Morillo, Donna Ellen Reece, Paula Rodríguez‐Otero et al. · 2025 · Blood
89. Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor
    Reeder M. Robinson, Leticia Reyes, Ravyn M. Duncan, Haiyan Bian, Eric D. Strobel, Sarah L. Hyman, Allen B. Reitz, Nathan G. Dolloff · 2019 · European Journal of Medicinal Chemistry
90. Plasma exchange and rituximab treatment for lenalidomide‐associated cold agglutinin disease
    David Lawrence Brauer, Bennett B. Edelman, Aaron P. Rapoport, John R. Hess, Görgün Akpek · 2012 · Transfusion
91. Management of disease- and treatment-related complications in patients with multiple myeloma
    Francesca Gay, Antonio Palumbo · 2010 · Medical Oncology
92. Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist
    Arleigh B. Robertson McCurdy, Martha Q. Lacy · 2013 · Therapeutic Advances in Hematology
93. Lenalidomide
    Lesley J. Scott, Katherine Ann Lyseng-Williamson · 2011 · Drugs
94. Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells in�vitro
    Linlin Yin, Xin‐Mian Wen, Qinghua Lai, Jing Li, Xiuwen Wang · 2018 · Oncology Letters
95. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study
    Joseph R Mikhael, Judith B. Manola, Amylou Constance Dueck, Suzanne R. Hayman, Kurt R. Oettel, Abraham Sebastian Kanate, Sagar Lonial, S. Vincent Rajkumar · 2018 · Blood Cancer Journal
96. Management of older patients with multiple myeloma
    Francesca Gay, Antonio Pierangelo Palumbo · 2011 · Blood Reviews
97. Targeted Therapy of Multiple Myeloma
    Nathan G. Dolloff, Giampaolo Talamo · 2012 · Advances in experimental medicine and biology
98. The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies
    Michael H. Huo, Alex C. Spyropoulos · 2010 · Journal of Thrombosis and Thrombolysis
99. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes
    Paul Gerard Guy Richardson, Robert Donald Harvey, Jacob P. Laubach, Philippe Moreau, Sagar Lonial, Jesús F. San Miguel · 2015 · Expert Review of Clinical Pharmacology
100. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
     Parameswaran Hari, MV Mateos, Rafat Abonour, Stefan Tobias Knop, William Bensinger, Heinz Ludwig, Kevin Song, Roman Hájek, Philippe Moreau, David Samuel DiCapua Siegel et al. · 2017 · Leukemia